- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT04391855
Infiltration de plaie avec du tramadol, de la dexmédétomidine ou du magnésium plus ropivacaïne pour soulager la douleur après une chirurgie de la colonne vertébrale
Effet de l'infiltration de la plaie avec du tramadol, de la dexmédétomidine ou du sulfate de magnésium en complément de l'anesthésique local sur le soulagement de la douleur après une chirurgie de la colonne vertébrale
The rationale for multimodal analgesia is to achieve additive or synergistic analgesic properties while decreasing the incidence of side effects by reducing the dose of each agent. Nociceptive stimuli are known to activate the release of the excitatory amino acid glutamate in the dorsal horn of the spinal cord. The resultant activation of NMDA receptors causes calcium entry into the cell and triggers central sensitization. This mechanism is involved in the perception of pain and mainly accounts for its persistence during the postoperative period.
Peri-incisional injection of local anesthetics is an effective method for pain relief after many surgical procedures, as it can reduce postoperative analgesic consumption. Ropivacaine is a propyl analog of bupivacaine with a longer duration of action with a much safer cardiotoxicity profile than bupivacaine. Thus, a combination of local anesthetic with other analgesic factors, such as opioids, dexmedetomidine, clonidine, ketamine, magnesium sulfate, dexamethasone is suggested for a better analgesic outcome.
Dexmedetomidine, a highly selective a2-adrenergic receptor agonist, has been the focus of interest for its broad spectrum (sedative, analgesic, and anesthetic sparing) properties, making it a useful and safe adjunct in many clinical applications. The intravenous, intramuscular, intrathecal, epidural, and perineural use of this agent enhances analgesic effects.
Tramadol hydrochloride is a synthetic analog of codeine that acts on both opioid (weak m receptor agonist) and nonopioid receptors (inhibits the reuptake of noradrenaline and serotonin as well as release stored serotonin from nerve endings) which play a crucial role in pain inhibition pathway. It also blocks nerve conduction which imparts its local anesthetics like action on peripheral nerves.
It was reported that NMDA antagonists could prolong the analgesic effect of bupivacaine to even a week, as well as inhibit hyperalgesia. Magnesium sulfate (MGS) is a non-competitive antagonist of N-methyl, D-aspartate (NMDA) receptors with an analgesic effect and is essential for the release of acetylcholine from the presynaptic terminals and, similar to calcium channel blockers (CCB), can prevent the entry of calcium into the cell.
Aim of the study is to evaluate and compare the postoperative analgesic efficacy of tramadol, dexmedetomidine, and magnesium when added to ropivacaine as an adjuvant for wound infiltration following spine surgery.
Aperçu de l'étude
Statut
Description détaillée
Each participant will receive standard monitoring (ECG, SpO2, capnography, SBP, oesophageal temperature) and intravenous access will be established. A standard anesthesia protocol will be applied involving propofol 2mg/kg (iv) and remifentanil in TCI (target-controlled infusion). Cis-atracurium 0.2 mg/kg (iv) will be given to facilitate endotracheal intubation. Anesthesia will be maintained with desflurane in a 50% air/O2 mixture A standard anesthesia protocol will be applied involving propofol 2mg/kg (iv) and remifentanil in TCI (target-controlled infusion). Cis-atracurium 0.2 mg/kg (iv) will be given to facilitate endotracheal intubation. Anesthesia will be maintained with air to oxygen mixture of 50%, and desflurane adjusted to achieve a target BIS between 40 and 50. Remifentanil target level will be titrated according to analgesic demands defined by a > 20% change of heart rate or blood pressure compared with baseline. The duration of both anesthesia and surgical procedure will be registered. Furthermore, the level of sedation upon anesthesia emergence will be recorded using the Ramsey sedation scale.
Postoperatively pain assessment will be performed by the Visual Analogue Scale (VAS) and Numerical Rating Scale (NRS) at anesthesia emergence and at 2, 4, 6, 12, 18, and 24 h after surgery conclusion. Time to first analgesic request and total analgesics consumption postoperatively (morphine equivalents) will be recorded.
Episodes of shivering, as well as episodes of nausea and vomiting (PONV) and other postoperative adverse events, will be recorded at emergence and 24 hours thereafter.
Finally, patients' global satisfaction will be assessed the second day and one month after surgery using the Quality of Recovery Scale(QoR-40). In the meantime, blood samples will be taken at the time before the surgical stimulus, 6 hours and 24 hours after wound infiltration to measure cortisol, TNF-a, and IL-6 plasma concentration.
Type d'étude
Inscription (Réel)
Phase
- Phase 4
Contacts et emplacements
Lieux d'étude
-
-
-
Thessaloniki, Grèce, 54636
- AHEPA University Hospital
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Adult patients aged between 18 and 80 years
- ASA Physical status 1 to 3
- Elective or semi-elective one-level lumbar laminectomy or discectomy surgery
- Signed informed consent
Exclusion Criteria:
- Chronic use of opioids
- Drugs or alcohol abuse
- Neurological disorders
- Local anesthetics toxicity
- Myopathy
- Cardiac conductance disturbances
- Hepatic failure
- Renal failure
- Pregnancy
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Tripler
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Tramadol with ropivacaine
Tramadol 2mg/kg with ropivacaine (10mg/ml) 100mg for wound infiltration |
A solution of tramadol 2mg/kg with ropivacaine hydrochloride (10mg/ml) 100mg mixture making up a total volume of 15ml will be infiltrated in the surgical trauma area before closure.
Autres noms:
|
|
Expérimental: Dexmedetomidine with ropivacaine
Dexmedetomidine 1μg/kg with ropivacaine (10mg/ml) 100mg for wound infiltration |
A solution of dexmedetomidine 1μg/kg with ropivacaine hydrochloride (10mg/ml) 100mg mixture making up a total volume of 15ml will be infiltrated in the surgical trauma area before closure.
Autres noms:
|
|
Expérimental: Magnesium with ropivacaine
Magnesium sulfate 10 mg/kg with ropivacaine (10mg/ml) 100mg for wound infiltration |
A solution of magnesium 10 mg/kg with ropivacaine hydrochloride (10mg/ml) 100mg mixture making up a total volume of 15ml will be infiltrated in the surgical trauma area before closure.
Autres noms:
|
|
Comparateur placebo: Placebo with ropivacaine
Ropivacaine (10mg/ml) 100mg with 5ml isotonic saline for wound infiltration |
A solution of ropivacaine hydrochloride (10mg/ml) 100mg with 5ml of isotonic saline 0.9% mixture making up a total volume of 15ml will be infiltrated in the surgical trauma area before closure.
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Analgesics consumption postoperatively in morphine equivalents
Délai: 24 hours after the emergence from anesthesia
|
The difference in analgesic consumption (assessed as mg of morphine equivalents) postoperatively after wound infiltration with tramadol plus ropivacaine, tramadol plus ropivacaine, magnesium sulfate plus ropivacaine or ropivacaine plus isotonic saline 0.9% |
24 hours after the emergence from anesthesia
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Time to first analgesic request in minutes
Délai: 24 hours after the emergence from anesthesia
|
The difference in the time frame (minutes) for analgesia request after emergence from anesthesia after wound infiltration with tramadol plus ropivacaine, tramadol plus ropivacaine, magnesium sulfate plus ropivacaine or ropivacaine plus isotonic saline 0.9% |
24 hours after the emergence from anesthesia
|
|
Pain intensity postoperatively
Délai: At 10 minutes after emergence from anesthesia, and 2, 4, 6, 12, 18 and 24 hours after the emergence from anesthesia
|
The difference in pain intensity postoperatively assessed by Visual Analogue Scale (graded from 0 defining absence of pain to 10 meaning extreme pain) or Numerical Pain Scale (graded from 0 defining no pain to 10 the worst pain ever experienced) after wound infiltration with tramadol plus ropivacaine, tramadol plus ropivacaine, magnesium sulfate plus ropivacaine or ropivacaine plus isotonic saline 0.9% |
At 10 minutes after emergence from anesthesia, and 2, 4, 6, 12, 18 and 24 hours after the emergence from anesthesia
|
|
Plasma concentration of TNF-a and IL-6
Délai: Before wound infiltration, and at 6 and 24 hours thereafter
|
Levels of TNF-a and IL-6 in pg/ml will be measured from blood samples at the times before surgical stimulus, at 6 hours and 24 hours after wound infiltration, as stress-response biomarkers. |
Before wound infiltration, and at 6 and 24 hours thereafter
|
|
Plasma concentration of cortisol
Délai: Before wound infiltration, and at 6 and 24 hours thereafter
|
Levels of cortisol (in mcg/dL) will be measured from blood samples at the times before surgical stimulus, at 6 hours and 24 hours after wound infiltration, as stress-response biomarkers. |
Before wound infiltration, and at 6 and 24 hours thereafter
|
Autres mesures de résultats
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Patients' sedation level after emergence
Délai: At 5 minutes after emergence from anesthesia
|
The level of sedation will be assessed after emergence using the Ramsey sedation scale in each participant, which ranges between 1 (anxious and restless patient) to 6 (unresponsive patient). |
At 5 minutes after emergence from anesthesia
|
|
Postoperative adverse effects
Délai: 24 hours after the emergence from anesthesia
|
The incidence of shivering, pruritus, nausea /vomiting, or any other adverse effect postoperatively after wound infiltration with tramadol plus ropivacaine, tramadol plus ropivacaine, magnesium sulfate plus ropivacaine or ropivacaine plus isotonic saline 0.9% |
24 hours after the emergence from anesthesia
|
|
Quality of Recovery
Délai: At 48 hours postoperatively and one month after hospital discharge
|
The quality of recovery and overall satisfaction of each participant will be assessed using the Quality of Recovery Scale (QoR-40) ranging from 0 the worst to 200 the best value. |
At 48 hours postoperatively and one month after hospital discharge
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Georgia Tsaousi, Aristotle University Of Thessaloniki
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- La douleur
- Manifestations neurologiques
- Maladies osseuses
- Maladies musculo-squelettiques
- Maladies du système nerveux
- Complications postopératoires
- Processus pathologiques
- Manifestations neurocomportementales
- Troubles de la perception
- Conditions pathologiques, signes et symptômes
- Signes et symptômes
- Douleur, Postopératoire
- Sténose spinale
- Agnosie
- Maladies de la colonne vertébrale
- Produits chimiques organiques
- Composés hétérocycliques, 1 anneau
- Composés hétérocycliques
- Préparations pharmaceutiques
- Lipides
- Azoles
- Imidazoles
- Anilides
- Amides
- Composés aniline
- Amines
- Produits chimiques inorganiques
- Solutions cristalloïdes
- Solutions isotoniques
- Solutions
- Éléments
- Métaux, lumière
- Métaux
- Alcools
- Cyclohexanols
- Hexanols
- Alcools gras
- Diméthylamines
- Méthylamines
- Métaux, terre alcaline
- Ropivacaïne
- Dexmédétomidine
- Tramadol
- Solution saline
- Magnésium
Autres numéros d'identification d'étude
- SpinInf
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .